Pivotal interplays between fecal metabolome and gut microbiome reveal functional signatures in cerebral ischemic strokeOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the relationship between the gut microbiome and metabolomic profiles in ischemic stroke by comparing three different body-fluid sample types: stool, urine, and plasma. The researchers used metagenomic sequencing of feces alongside untargeted metabolomics of feces, plasma, and urine to determine which sample type most closely tracks with gut microbial composition and disease status. Differential analyses identified key microbes and metabolites distinguishing stroke from health, and Spearman's rank correlation plus linear regression were used to link microbiota to metabolites across the three sample types.
Who was studied?
The abstract describes ischemic stroke patients and healthy volunteers, but it does not give the exact number of participants, age range, or other demographic details. Based on the methods described (metagenomic sequencing of feces plus paired feces, plasma, and urine metabolomics), the cohort appears to be a case-control clinical study directly recruiting stroke patients and matched or unmatched healthy controls, rather than a purely public or archival dataset.
What were the most important findings?
Untargeted metabolomics showed that fecal samples contained the most abundant and most numerous identified metabolic features compared with urine and plasma. Feces also yielded the highest number of metabolites that differed significantly between ischemic stroke patients and healthy subjects, ranking above urine and plasma in this respect. This indicates that stool is the metabolic sample type most informative for capturing metabolomic differences associated with ischemic stroke.
What are the greatest implications of this study?
The findings suggest that fecal metabolomics, rather than urine or plasma, may be the preferred biological sample for studying gut-microbiome-linked metabolic signatures of ischemic stroke. This has practical implications for designing future microbiome-disease studies, since sample choice affects the ability to detect meaningful microbiota-metabolite associations. By pairing fecal metagenomics with fecal metabolomics, researchers may be better positioned to uncover functional gut-microbiome signatures relevant to cerebrovascular disease.